The inhibitory effects of nanosize delivery system for antisense oligonucleotide of hTERT on EC9706 cells

Cancer Biology and Therapy

Volumn 6, Issue 3, 2007, Pages 329-334

  Zhang, Zhenzhong ^a   Wang, Baiyan ^a   Li, Huixiang ^a   Zhou, Tianyang ^a   Zhang, Lan ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Antisense oligonucleotides; Esophageal squamous cell carcinoma EC9706; Gene therapy; hTERT; Nanosize delivery system

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 34548258746     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.3.3662     Document Type: Article

References (24)

1. Masutomi K, Kaneko S, Yasukawa M, Arai K, Murakami S, Kobayashi K. Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma. Oncogene 2002; 21:5946-50.
2. Middleman EJ, Choi J, Venteicher AS, Cheung P, Artandi SE. Regulation of cellular immortalization and steady-state levels of the telomerase reverse transcriptase through its carboxy-terminal domain. Mol Cell Biol 2006; 26:2146-59.
3. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90:785-95.
4. Yokoyama Y, Takahashi Y, Shinohara A, Wan X, Takahashi S, Niwa K, Tamaya T. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem Biophys Res Commun 2000; 273:316-21.
5. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997; 17:498-502.
6. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol 2002; 3:672-83.
7. Arnedo A, Espuelas S, Irache JM. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 2002; 244:59-72.
8. Junghans M, Kreuter J, Zimmer A. Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res 2000; 28:E45.
9. Chavany C, Le Doan T, Couvreur P, Puisieux F, Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 1992; 9:441-49.
10. Amioka T, Kitadai Y, Hiyama T, Tanaka S, Yoshihara M, Haruma K, Chayama K. Expression of human telomerase reverse transcriptase mRNA in esophageal cancers and precancerous lesions. Oncol Rep 2004; 11:51-5.
11. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003; 24:1167-76.
12. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods 1999; 18:286-95, 322.
13. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997; 276:561-7.
14. Shay JW, Wright WE. Telomerase therapeutics for cancer: Challenges and new directions. Nat Rev Drug Discov 2006; 5:577-84.
15. Zhang P, Xu Q, Chen WT, Duan LQ, Zhang ZY, Zhou XJ. Synergistic down-regulation of telomerase by all-trans retinoic acid and antisense oligonucleotide in oral squamous cell carcinoma cell line (Tca8113). Oral Oncol 2005; 41:909-15.
16. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998; 58:1558-61.
17. Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, Daidone MG, Zaffaroni N. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer 2005; 41:624-34.
18. Fu XH, Zhang JS, Zhang N, Zhang YD. Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line. World J Gastroenterol 2005; 11:785-90.
19. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm 2001; 229:1-21.
20. Wong SC, Yu H, Moochhala SM, So JB. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells. Anticancer Res 2003; 23:465-9.
21. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, Meye A. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 2003; 9:3794-800.
22. Pang JX, Cheng XY, Xu W, Wu SG. Antisense Sp1 oligodeoxynucleotide decreases telomerase activity by inhibiting hTERT mRNA expression in Jurkat T cells. Acta Pharmacol Sin 2003; 24:91-6.
23. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000; 28:669-77.
24. Fujimoto K, Takahashi M. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Biochem Biophys Res Commun 1997; 241:775-81.